Free scoping read. A written assessment of your manuscript in two business days, at no cost.

Start one
Contents

Academy · Research Publication · TRIP interventions

Translating Research into Practice (TRIP) Interventions: Definition and Evidence

TRIP (Translating Research into Practice) began as a named funding programme and became a general label for interventions intended to close the gap between what the evidence supports and what services deliver. The label is useful, but the evidence behind it is weaker and more heterogeneous than the volume of publication suggests, and investigators designing a TRIP study should take this into account from the outset.

Pubrica AcademyWritten by the medical writing and biostatistics teams Reviewed byPubrica biostatistics team Published9 October 2026 Last checked9 October 2026 Reading time14 minutes Sources29 peer-reviewed

The Agency for Healthcare Research and Quality created TRIP as a demonstration programme intended to fund implementation projects in real settings and to generate generalisable knowledge about what changes practice. Three decades later, “TRIP intervention” is used loosely for any multi-component effort to put research findings into routine use, which obscures an important distinction. The programme had a specific design — cooperative agreements, defined award sizes, bounded project periods — whereas the generic category has no design at all. Authors writing about or designing such an intervention should therefore first state which meaning is intended.

Learning objectives

  • Describe the Agency for Healthcare Research and Quality (AHRQ) TRIP programme, including the funding structure that shaped what could be studied
  • Identify the components from which a TRIP intervention is typically assembled, and why their combination matters more than any single component
  • State what the knowledge translation evidence base currently supports, including its methodological weaknesses
  • Use the translation time-lag literature accurately rather than repeating the 17-year figure
  • Design a TRIP study whose null result would be interpretable
  • Report a translation project so that a reader can determine what was delivered

Common misconceptions

  • “TRIP is a type of intervention.” It is a funding programme that became a category label. AHRQ’s TRIP II request for applications offered up to 7.0 million dollars in the first year for roughly 12 to 18 cooperative-agreement demonstration projects — a programme design, not an intervention design.
  • “The evidence shows translation interventions work.” It indicates that some of them are effective in some circumstances. Scott and colleagues, in Implementation Science, screened 2,638 records and 1,172 full texts to include 32 studies of knowledge translation in the allied health professions: only 4 reported statistically significant positive effects on their primary outcome, and 23 of 29 quantitative studies were rated methodologically weak.
  • “Research takes 17 years to reach practice.” Morris, Wooding and Grant reviewed 23 papers that quantified time lags and found the figure rests on a handful of incompatible estimates. Correcting the Balas and Boren estimate for how single studies had been summed moved it from 17 years to 23 years.
  • “Multi-component interventions are stronger than single-component ones.” They are more difficult to interpret. Adding components without stating the mechanism through which each operates produces a study that cannot explain its own result, irrespective of the direction of that result.
  • “Audit and feedback is a weak intervention.” It is the most extensively evidenced intervention available, which reflects the state of the field rather than constituting a dismissal. Ivers and colleagues, in the Cochrane Database of Systematic Reviews, found small average improvements that vary substantially with how the feedback is designed.

Origins of TRIP and the current meaning of the term

TRIP began as a specific initiative. The Agency for Healthcare Research and Quality, working with the Department of Veterans Affairs Health Services Research and Development Service, established Translating Research into Practice as a funding programme whose purpose was to support implementation projects in operating health systems rather than in research settings, and to extract generalisable lessons from them 26,28.

The distinction between the programme and the generic label matters for two reasons. First, the programme’s structure constrained what could be studied: a bounded project period and a fixed award size rule out long-term maintenance follow-up and large cluster designs, which partly explains why the resulting literature is weighted toward short-horizon process outcomes. Second, describing any multi-component implementation effort as a “TRIP intervention” implies a shared design that does not exist. When the term appears in a paper, readers should establish whether it refers to the funded programme, to a project funded under it, or to a category the authors have assigned themselves.

The intellectual framing around TRIP comes from the knowledge translation literature. Grimshaw, Eccles, Lavis, Hill and Squires, in Implementation Science, set out what knowledge translation of research findings requires; Grol and Grimshaw, in the Lancet, describe the move from best evidence to best practice; Grimshaw and Eccles, in the Medical Journal of Australia, ask whether evidence-based implementation of evidence-based care is possible 11,19,24. That question constitutes the appropriate starting point for this subject.

Programme design and its outputs

The second phase of the programme is documented in sufficient detail to be instructive. AHRQ’s TRIP II request for applications offered up to 7.0 million dollars in the first year for roughly 12 to 18 cooperative-agreement demonstration projects, with awards of 300,000 to 1.5 million dollars in total annual costs over project periods of no more than three years 28.

These parameters should be read as design constraints rather than administrative detail. A three-year maximum means that the maintenance question — whether the change persists once the project team leaves — is structurally unanswerable within a single award. An award ceiling in that range funds a project across a small number of sites, not the dozens a cluster-randomised design would require for adequate power on a patient outcome. The cooperative agreement mechanism, in which the funder participates in the work rather than merely monitoring it, also shapes what is reported: it tends to produce detailed implementation description and relatively weak effect estimation.

None of this constitutes a criticism of the programme, which was designed to generate practical learning in real systems. It is, rather, an argument for reading its outputs in light of their particular strengths. For readers seeking to understand what happened when a specific evidence-based practice met a specific service, this literature is valuable. For readers seeking a pooled effect estimate for a class of intervention, it is likely to prove inadequate, and the reason lies in the funding structure rather than in the investigators.

7.0 million dollarsoffered in the first year
12 to 18cooperative-agreement demonstration projects anticipated
300,000 to 1.5 million dollarsper award in total annual costs
3 yearsmaximum project period, which is why maintenance is rarely assessed in this literature

The TRIP II programme parameters, from Agency for Healthcare Research and Quality. Translating Research Into Practice (TRIP) II: request for applications RFA-HS-00-008. These are design constraints on what the resulting literature could measure, not administrative detail.

Components of a TRIP intervention

A translation intervention is almost always an assembly of components. The components recur across projects, and sound practice is to name each one and state the mechanism through which it is intended to work, because a bundle whose components have no stated mechanisms cannot explain its own result.

The recurring components are: a local gap measurement that makes the problem visible; audit with feedback, usually with peer comparison; a change to the record system or the default workflow; clinical champions or opinion leaders; education, either didactic or academic detailing; reminders at the point of decision; and patient-directed components 21,24. Greenhalgh, Robert, Macfarlane, Bate and Kyriakidou’s diffusion review in the Milbank Quarterly explains why the assembly matters: adoption depends on compatibility with existing routines, on local relational structures and on reversibility, so the same component embedded in two services may be effective in one and not in the other 18.

The practical implication is a hierarchy that may be applied when selecting components. Changes that remove effort — a default, a template field, a pre-populated order set — persist with the least maintenance. Changes that redirect existing effort — a slot in a meeting that already takes place — persist moderately well. Changes that add effort — a new form, a new meeting, a standing commitment to additional documentation — revert when attention moves elsewhere. This hierarchy is not a finding from a trial; it is an inference from the diffusion literature and is presented as such.

Components a translation intervention is assembled from, with the mechanism each works through

ComponentIntended mechanismEffort it places on the clinicianPersistence after the project
Local gap measurementMakes the discrepancy visible and specific to this service, which is what makes it credibleNone, if extracted from existing recordsPersists only if the indicator is adopted into routine reporting
Audit and feedback with peer comparisonSocial comparison and self-monitoringLow, but requires attention to the reportReverts when reports cease; the most extensively evidenced component, yet still associated with a small average effect
Record system or default changeRemoves the need to remember; changes the path of least resistanceNegative — it removes effortHigh. This is the component most likely to outlast the project
Point-of-decision reminderCues the behaviour at the moment it is requiredLow per instance, high in aggregate if poorly targetedModerate, and degrades as alert fatigue accumulates
Champions or opinion leadersWorks through local relational structures rather than informationLow for most, high for the championLow. Depends on named individuals remaining in post
Education or academic detailingBuilds capability where capability is the actual constraintModerate, and the time is drawn from clinical workLow on its own; decays without reinforcement

Components as they recur across the translation literature cited in this article. The effort and persistence columns are inferences from the diffusion evidence — principally Greenhalgh T, Robert G, Macfarlane F, Bate P, Kyriakidou O, Milbank Quarterly — rather than findings from comparative trials, and are offered as a design heuristic.

A worked example: a TRIP project based on the record system

Ornstein reported a TRIP project conducted in the PPRNet primary care research network, using electronic medical records to support primary and secondary prevention of coronary disease 27. The case is instructive for three reasons.

First, the intervention is embedded in the record system rather than layered on top of it, which places it in the effort-removing category. Second, it operates in a practice-based research network, which provides access to multiple real sites with comparable data extraction — the infrastructure problem on which most translation projects fail before they begin. Third, the target is a preventive practice with a measurable process indicator, the kind of target for which a translation intervention has a realistic prospect of demonstrating change within a short project period.

These three features approximate the specification for a translation project capable of producing an interpretable result: an effort-reducing mechanism, an existing multi-site data infrastructure, and a process indicator that changes faster than a patient outcome. A project lacking all three — an added-effort intervention at a single site targeting mortality — is common and rarely informative. Our page on electronic health records covers what the record system can and cannot be made to do, and the challenges in medical data collection explains why multi-site extraction is more difficult than it may appear.

Scope of the supporting evidence

Many reviews of TRIP interventions understate the weaknesses of this evidence, which does not assist those designing studies. The most informative single appraisal is Scott, Albrecht, O’Leary, Ball, Hartling, Hofmeyer, Jones, Klassen, Kovacs Burns, Newton, Thompson and Dryden’s systematic review in Implementation Science, with its protocol published separately by Hartling and colleagues. They screened 2,638 records and assessed 1,172 full texts to include 32 studies of knowledge translation strategies in the allied health professions: 29 quantitative and 3 qualitative 12,13. Only 4 reported statistically significant positive effects on their primary outcome. Twenty-three of the 29 quantitative studies were rated methodologically weak. Four studies reported patient outcomes at all.

Three conclusions follow. The first concerns effect: the field has not demonstrated reliable effects on primary outcomes for this professional group. The second concerns method, and it is more consequential: when 23 of 29 studies are methodologically weak, the four positive results cannot be taken at face value, because weak designs are precisely those that produce spurious positives 12,15. The third concerns outcome selection: a literature in which four of thirty-two studies measure patient outcomes is a literature about process.

The appropriate response is not to abandon the enterprise but to design against these weaknesses. This requires a concurrent control rather than a before-and-after comparison, a pre-specified primary outcome, a process evaluation so that a null result is interpretable, and an explicit decision about whether the project can measure a patient outcome or should confine itself to a process outcome and state as much. Hulscher, Laurant and Grol, in Quality and Safety in Health Care, set out the process evaluation requirements 25.

What a systematic review of knowledge translation in the allied health professions found

StageNumberWhat it tells you
Records screened2,638The published volume is large
Full texts assessed1,172A high proportion looked potentially relevant on title and abstract
Studies included32 (29 quantitative, 3 qualitative)The eligible evidence base for one professional group is small
Reporting significant positive effects on the primary outcome4Reliable effects on primary outcomes have not been demonstrated
Quantitative studies rated methodologically weak23 of 29The most consequential finding: weak designs are the ones that generate spurious positives, so the four positive results cannot be read at face value
Studies reporting patient outcomes4This is a literature about process, irrespective of the claims made in its abstracts

Scott SD, Albrecht L, O’Leary K, Ball GDC, Hartling L, Hofmeyer A, Jones CA, Klassen TP, Kovacs Burns K, Newton AS, Thompson D, Dryden DM. Systematic review of knowledge translation strategies in the allied health professions. Implementation Science. Protocol published separately by Hartling L and colleagues.

Audit and feedback: the most studied component and its limits

If a single component must carry a translation intervention, it will usually be audit and feedback, because it has the strongest evidence base. Ivers, Jamtvedt, Flottorp and colleagues, and subsequently Ivers, Yogasingam, Lacroix and colleagues in the Cochrane Database of Systematic Reviews, found that audit and feedback produces small average improvements in professional practice, with effect size varying considerably with the design and delivery of the feedback 1,2.

A notable development is the shift from asking whether it works to asking how it should be designed. Foy, Skrypak, Alderson, Ivers, McInerney, Stoddart, Ingham and Keenan set out an agenda for revitalising audit and feedback to improve patient care in the BMJ, published in volume 368 as article m213 4. Wagstaff, Vindrola, Fulop and Moonesinghe, in the same journal, argue for understanding and responding to local context as the route to improvement. Both treat the design of feedback as the open research question, a framing consistent with the Cochrane findings.

One cautionary result is relevant to any investment in feedback redesign. Wright-Hughes, Willis, Wilson, Weller and colleagues, in Implementation Science, ran a randomised fractional factorial screening experiment testing six modifications to audit feedback with clinicians, managers and audit staff drawn from five UK national clinical audit programmes, and found that no single modification independently improved intention to act. Willis, Wright-Hughes and colleagues report the associated programme of work. The implication is not that feedback design is irrelevant but that the effect is unlikely to reside in any single modification, which should temper proposals that promise improvement from a redesigned report template.

The translation lag and its relevance to the economic case

The 17-year claim is the most frequently repeated statistic in this field, and it does not withstand scrutiny 15. Morris, Wooding and Grant, in the Journal of the Royal Society of Medicine, reviewed 23 papers that quantified translation time lags and found the frequently stated average of 17 years rests on only a handful of estimates whose start and end points are defined incompatibly — from basic discovery to first publication to first trial, and from first clinical use to guideline inclusion to majority adoption 8,12,15. Correcting the Balas and Boren estimate for the way single studies had been added together changed the lag from 17 years to 23 years.

The consequence for any economic argument for translation work is direct and has been quantified. Morris, Wooding and Grant report that in a UK cardiovascular research study, varying the assumed translation lag from 10 to 25 years changed the health-benefit rate of return from 13% to 6% 15. A single unstated assumption therefore more than halves the headline return. Glover, Buxton, Guthrie and colleagues’ estimates of returns to UK publicly funded cancer-related research, and Glover, Montague, Pollitt and colleagues’ equivalent for musculoskeletal disease research, are the substantive work in this area; Hanney, Mugford, Grant and Buxton’s analysis of antenatal corticosteroid research is a particularly instructive case study, because it examines a specific instance of strong evidence and slow uptake 5,9,16.

Hanney, Wooding, Sussex and Grant’s analysis of COVID-19 vaccine development, and Trochim, Kane, Graham and Pincus’s process marker model in Clinical and Translational Science, indicate the alternative: to specify and time the markers that a given project will pass, rather than invoking an aggregate interval that cannot be defended 3,14. Our page on EBP in technology development covers the same problem on the development side.

Designing a TRIP study with an interpretable null result

The test of a translation study design is whether a null result would be informative. Most designs fail this test, because a null result is consistent with the intervention not working, not being delivered, being delivered to the wrong people, or being delivered in an unrecognisable form. Four design decisions separate these possibilities.

A concurrent comparison should be used, because a before-and-after design in a service that is also undertaking other improvement work cannot attribute change. One primary outcome should be pre-specified and identified as either a process or a patient outcome; a study with six co-primary process measures will find some significant result, and that finding will not replicate. Delivery and fidelity should be measured as outcomes in their own right, not treated as project management. Finally, the mechanism through which each component is intended to work should be stated, so that a partial failure can be diagnosed.

Buckwalter, Cullen, Hanrahan, Kleiber, McCarthy, Rakel, Tucker and colleagues’ revised Iowa Model provides a practical sequence with decision points; Hill, Guihan, Hogan, Smith, LaVela, Weaver, Evans and colleagues show how PARIHS can be used for prospective as well as retrospective analysis; Schaffer, Sandau and Diedrick, in the Journal of Advanced Nursing, compare the available models 6,7,10. Mainz, in the International Journal for Quality in Health Care, covers the indicator definition work without which none of the measurement is reproducible 23. Our implementation steps page sets out the sequence in full, and performance gap assessment covers establishing the baseline.

The aims and design paragraph of a translation project proposal

A null result here would be uninterpretable

This TRIP intervention aims to improve adherence to the guideline across the participating services through a multifaceted strategy comprising education, audit and feedback, clinical champions and the development of a toolkit. Outcomes will include guideline adherence, clinician knowledge, patient satisfaction and clinical outcomes, measured before and after implementation. We hypothesise that the multifaceted intervention will significantly improve adherence and patient outcomes.

“Multifaceted strategy” with no mechanisms. Four components are bundled, none with a stated mechanism, so no result can be attributed to anything.

Four outcomes and no primary. With adherence, knowledge, satisfaction and clinical outcomes all assessed, one of them will reach significance, and the result will not replicate.

Before-and-after in an active service. Any change is confounded by other concurrent activity in the service, which in a quality-improvement environment is invariably present.

No delivery or fidelity measurement. A null result cannot be distinguished from non-delivery, which is the defect Hulscher, Laurant and Grol identify as making process evaluation non-optional.

“Significantly improve patient outcomes” is not proportionate. Scott and colleagues found 4 of 32 studies reported significant positive primary-outcome effects and 4 reported patient outcomes at all; the Cochrane audit and feedback reviews find small average effects.

Every possible result means something

The target practice is a single recommended action with a measurable process indicator, defined in Appendix 1 to the level at which an independent analyst could reproduce the count. The primary outcome is that process indicator; it is a process outcome and not a patient outcome, and the project is not powered to detect a change in the patient outcome, which we state here rather than report as an exploratory finding later. The design is a stepped comparison across participating sites so that each site’s later period is compared against concurrently unexposed sites, because a before-and-after comparison in services that are simultaneously running other improvement work cannot attribute change. Three components are included, each with a stated mechanism: a change to the record template, intended to remove the need to remember; audit with peer comparison, intended to make the local gap visible; and a short item in an existing team meeting, intended to redirect rather than add time. We have deliberately not included a champion component, because its persistence depends on named individuals remaining in post and we cannot guarantee that over the project period. Delivery and fidelity are outcomes in their own right: we will report what proportion of intended recipients received each component, in what form, and what clinicians did instead on occasions when the action was not taken. Maintenance will not be assessed within the project period, and we say so rather than implying otherwise.

One pre-specified primary outcome, explicitly labelled as a process measure, with the power limitation stated in advance rather than excused afterwards.

A concurrent comparison, so change can be attributed rather than merely observed.

Each component carries its mechanism, which makes a partial failure diagnosable and tells a replicator what to copy.

A component is deliberately excluded with the reason given, which is stronger evidence of design thinking than adding one more.

Delivery, fidelity and what people did instead are measured as outcomes, so every possible result is interpretable.

The maintenance limitation is declared, consistent with a bounded project period, rather than left for a reviewer to find.

A reviewer’s first question about a translation study concerns what a negative result would reveal. The first version provides no answer; the second answers the question within the proposal, which also makes a positive result credible should one be obtained.

Reporting a translation project

The most common defect in published translation work is that a reader cannot determine what was delivered. The intervention is described as designed rather than as implemented, so the paper reports a plan and an outcome without the intervening process. That is the gap that a process evaluation fills and that reporting guidance for improvement work is intended to close.

Authors should report the components separately with their mechanisms; the proportion of intended recipients who received each component, and in what form; what participants did instead when they did not perform the target action; and the maintenance position at the end of the project, even if it was not assessed. The statement “maintenance was not assessed within the project period” is legitimate and informative and, given the three-year ceiling on the original TRIP awards, an accurate one for much of this literature. Our SQUIRE and EBP and quality improvement checklist pages cover the reporting items, and medical writing support covers the manuscript.

Key points

Key points

TRIP started as an AHRQ demonstration programme and became a loose label, and the distinction is important: the TRIP II request for applications offered up to 7.0 million dollars in the first year for roughly 12 to 18 cooperative-agreement projects, awards of 300,000 to 1.5 million dollars, and project periods of no more than three years — constraints that explain why this literature is rich in implementation description, weighted toward process outcomes, and almost silent on maintenance. The evidence should be interpreted with caution. Scott and colleagues screened 2,638 records and 1,172 full texts to include 32 studies of knowledge translation in the allied health professions, of which only 4 showed significant positive primary-outcome effects, 23 of 29 quantitative studies were rated methodologically weak, and 4 reported patient outcomes at all. Audit and feedback remains the best-evidenced single component and still yields only small average improvements, and a fractional factorial experiment across five UK national audit programmes found no single one of six feedback modifications independently improved intention to act. Studies should be designed so that a null result is interpretable: concurrent comparison, one pre-specified primary outcome, stated mechanisms, measured fidelity. The economic case should not be anchored to the 17-year lag, since varying the assumed lag from 10 to 25 years moved a UK cardiovascular return estimate from 13% to 6%.

Application to your study

Application to your study

  1. The intended meaning of TRIP should be specified. The introduction should distinguish the AHRQ programme, a project funded under it, and the generic category. Reviewers in this field notice when the three are conflated.
  2. A single primary outcome should be named and labelled. The outcome should be labelled as a process or a patient outcome. If the project cannot be powered for a patient outcome, this should be stated in the protocol rather than reported later as exploratory.
  3. Each component should be paired with a mechanism. For each component, the statement “this component is intended to change X by doing Y” should be written; any component for which it cannot be written should be removed.
  4. Components that remove effort should be preferred. A template change, a default or a pre-populated order set outlasts a champion network or a standing meeting.
  5. A concurrent comparison should be incorporated. Stepped introduction across sites is usually feasible where randomisation is not, and it is the difference between observing change and attributing it.
  6. Delivery and fidelity should be measured as outcomes. The proportion of participants who received each component, the form in which it was received, and what was done instead should be reported. This information makes a null result publishable.
  7. The maintenance limitation should be declared. If the project period cannot establish whether the change persists, the authors should state this limitation explicitly.

Frequently asked questions

TRIP stands for Translating Research into Practice. It originated as a funding programme established by the Agency for Healthcare Research and Quality, working with the Department of Veterans Affairs Health Services Research and Development Service, to support implementation projects in operating health systems and extract generalisable lessons. The term is now also used generically for any multi-component intervention intended to move research findings into routine care, which blurs a distinction that should be preserved: the programme had a defined structure, whereas the generic category has none. When the term appears in a paper, readers should establish whether it refers to the programme, a project funded under it, or a label the authors assigned themselves.

The TRIP II request for applications offered up to 7.0 million dollars in the first year for roughly 12 to 18 cooperative-agreement demonstration projects, with individual awards of 300,000 to 1.5 million dollars in total annual costs and project periods of no more than three years. These parameters are design constraints rather than administrative detail. A three-year ceiling makes the maintenance question — whether the change persists after the project team leaves — structurally unanswerable within one award. An award of that size funds a small number of sites, not the number a cluster-randomised design requires for adequate power on a patient outcome. The strengths and gaps of the literature follow directly from these constraints.

Some of them are effective in some circumstances, and the evidence is weaker than the volume of publication implies. The clearest appraisal is Scott, Albrecht, O’Leary, Ball, Hartling and colleagues’ systematic review in Implementation Science: 2,638 records screened, 1,172 full texts assessed, 32 studies included — 29 quantitative and 3 qualitative — of which only 4 reported statistically significant positive effects on their primary outcome, with 23 of the 29 quantitative studies rated methodologically weak and only 4 studies reporting patient outcomes at all. The methodological finding is the important one: weak designs are exactly those prone to spurious positives, so the four positive results cannot be read at face value.

Yes, although expectations should be calibrated. Ivers, Jamtvedt, Flottorp and colleagues, and later Ivers, Yogasingam, Lacroix and colleagues in the Cochrane Database of Systematic Reviews, found that audit and feedback produces small average improvements in professional practice, varying considerably with how the feedback is designed and delivered. The field has shifted to asking how it should be designed: Foy, Skrypak, Alderson, Ivers and colleagues set out an agenda for revitalising audit and feedback in the BMJ (volume 368, article m213), and Wagstaff and colleagues argue for responding to local context. A cautionary finding is that Wright-Hughes, Willis and colleagues tested six feedback modifications in a randomised fractional factorial experiment across five UK national clinical audit programmes and found that no single modification independently improved intention to act.

The figure is not supported by its source. Morris, Wooding and Grant, in the Journal of the Royal Society of Medicine, reviewed 23 papers quantifying translation time lags and found the commonly quoted 17-year average rests on only a handful of estimates whose start and end points are incompatibly defined — discovery, publication or first trial at one end; first use, guideline inclusion or majority adoption at the other. Correcting the Balas and Boren estimate for how single studies had been summed moved the figure from 17 years to 23 years. A statistic that shifts by six years on a summation correction cannot anchor a timeline or an economic case. Authors should instead time their own process markers, as Trochim and colleagues propose.

Substantially. Morris, Wooding and Grant report that in a UK cardiovascular research study, varying the assumed translation lag from 10 to 25 years changed the health-benefit rate of return from 13% to 6% — more than halving the headline return on the basis of a single assumption that the same paper shows to be poorly characterised. The appropriate response is to present a sensitivity range rather than a point estimate, and to state the lag assumption prominently, because assessors are likely to examine it first. Glover, Buxton, Guthrie and colleagues on UK cancer research returns, and Glover, Montague, Pollitt and colleagues on musculoskeletal research, show how such estimates are constructed and where the assumptions lie.

Four design decisions are essential. First, a concurrent comparison should be used rather than a before-and-after design, since any service simultaneously running other improvement work confounds a simple pre-post contrast. Second, one primary outcome should be pre-specified and explicitly labelled as process or patient, rather than several co-primary outcomes among which one will reach significance. Third, delivery and fidelity should be measured as outcomes in their own right, so that non-delivery can be distinguished from ineffectiveness — the point Hulscher, Laurant and Grol make about process evaluation in Quality and Safety in Health Care. Fourth, a mechanism should be stated for every component, so that partial failure can be diagnosed rather than merely observed.

Components that remove effort, rather than add it, persist longest. A change to a record template, a default setting or a pre-populated order set alters the path of least resistance and therefore survives without maintenance. Components that redirect existing effort, such as a short item in a meeting that already takes place, persist moderately. Components that add effort — a new form, a new meeting, a standing commitment to additional documentation — revert when attention moves elsewhere, and champion-based components additionally depend on named individuals remaining in post. This ranking is an inference from Greenhalgh and colleagues’ diffusion review in the Milbank Quarterly, where compatibility with existing routines predicts persistence, rather than a finding from a head-to-head trial.

References

  1. Ivers N, Yogasingam S, Lacroix M, et al. Audit and feedback: effects on professional practice. Cochrane Database of Systematic Reviews. 2025:CD000259. doi:10.1002/14651858.CD000259.pub4 read 9 October 2026. doi.org/10.1002/14651858.CD000259.pub4
  2. Ivers N, Jamtvedt G, Flottorp S, et al. Audit and feedback: effects on professional practice and healthcare outcomes. Cochrane Database of Systematic Reviews. 2012;6:CD000259. doi:10.1002/14651858.CD000259.pub3 read 9 October 2026. doi.org/10.1002/14651858.CD000259.pub3
  3. Hanney SR, Wooding S, Sussex J, Grant J. From COVID-19 research to vaccine application: why might it take 17 months not 17 years and what are the wider lessons? Health Research Policy and Systems. 2020;18:61. doi:10.1186/s12961-020-00571-3 read 9 October 2026. doi.org/10.1186/s12961-020-00571-3
  4. Foy R, Skrypak M, Alderson S, Ivers N, McInerney B, Stoddart J, Ingham J, Keenan D. Revitalising audit and feedback to improve patient care. BMJ. 2020;368:m213. doi:10.1136/bmj.m213 read 9 October 2026. doi.org/10.1136/bmj.m213
  5. Glover M, Montague E, Pollitt A, et al. Estimating the returns to United Kingdom publicly funded musculoskeletal disease research in terms of net value of improved health outcomes. Health Research Policy and Systems. 2018;16:1. doi:10.1186/s12961-017-0276-7 read 9 October 2026. doi.org/10.1186/s12961-017-0276-7
  6. Buckwalter KC, Cullen L, Hanrahan K, Kleiber C, McCarthy AM, Rakel B, Tucker S, et al. Iowa Model of Evidence-Based Practice: Revisions and validation. Worldviews on Evidence-Based Nursing. 2017;14(3):175-182. doi:10.1111/wvn.12223 read 9 October 2026. doi.org/10.1111/wvn.12223
  7. Hill JN, Guihan M, Hogan TP, Smith BM, LaVela SL, Weaver FM, Evans CT, et al. Use of the PARIHS Framework for retrospective and prospective implementation evaluations. Worldviews on Evidence-Based Nursing. 2017;14(2):99-107. doi:10.1111/wvn.12211 read 9 October 2026. doi.org/10.1111/wvn.12211
  8. Hanney SR, Castle-Clarke S, Grant J, Guthrie S, Henshall C, Mestre-Ferrandiz J, Pistollato M, Pollitt A, Sussex J, Wooding S. How long does biomedical research take? Studying the time taken between biomedical and health research and its translation into products, policy, and practice. Health Research Policy and Systems. 2015;13:1. doi:10.1186/1478-4505-13-1 read 9 October 2026. doi.org/10.1186/1478-4505-13-1
  9. Glover M, Buxton M, Guthrie S, et al. Estimating the returns to UK publicly funded cancer-related research in terms of the net value of improved health outcomes. BMC Medicine. 2014;12:99. doi:10.1186/1741-7015-12-99 read 9 October 2026. doi.org/10.1186/1741-7015-12-99
  10. Schaffer MA, Sandau KE, Diedrick L. Evidence-based practice models for organizational change: overview and practical applications. Journal of Advanced Nursing. 2013;69(5):1197-1209. doi:10.1111/j.1365-2648.2012.06122.x read 9 October 2026. doi.org/10.1111/j.1365-2648.2012.06122.x
  11. Grimshaw JM, Eccles MP, Lavis JN, Hill SJ, Squires JE. Knowledge translation of research findings. Implementation Science. 2012;7:50. doi:10.1186/1748-5908-7-50 read 9 October 2026. doi.org/10.1186/1748-5908-7-50
  12. Scott SD, Albrecht L, O'Leary K, Ball GDC, Hartling L, Hofmeyer A, Jones CA, Klassen TP, Kovacs Burns K, Newton AS, Thompson D, Dryden DM. Systematic review of knowledge translation strategies in the allied health professions. Implementation Science. 2012;7:70. doi:10.1186/1748-5908-7-70 read 9 October 2026. doi.org/10.1186/1748-5908-7-70
  13. Hartling L, Dryden DM, Ball GDC, O'Leary K, Albrecht L, Scott SD, Hofmeyer A, Jones CA, Kovacs Burns K, Newton AS, Thompson D, Klassen TP. A protocol for a systematic review of knowledge translation strategies in the allied health professions. Implementation Science. 2011;6(1):58. read 9 October 2026. doaj.org
  14. Trochim W, Kane C, Graham M, Pincus HA. Evaluating translational research: a process marker model. Clinical and Translational Science. 2011;4:153-162. doi:10.1111/j.1752-8062.2011.00291.x read 9 October 2026. doi.org/10.1111/j.1752-8062.2011.00291.x
  15. Morris ZS, Wooding S, Grant J. The answer is 17 years, what is the question: understanding time lags in translational research. Journal of the Royal Society of Medicine. 2011;104(12):510-520. doi:10.1258/jrsm.2011.110180 read 9 October 2026. doi.org/10.1258/jrsm.2011.110180
  16. Hanney S, Mugford M, Grant J, Buxton M. Assessing the benefits of health research: lessons from research into the use of antenatal corticosteroids for the prevention of neonatal respiratory distress syndrome. Social Science & Medicine. 2005;60:937-947. doi:10.1016/j.socscimed.2004.06.038 read 9 October 2026. doi.org/10.1016/j.socscimed.2004.06.038
  17. Dawes M, Summerskill W, Glasziou P, et al. Sicily statement on evidence-based practice. BMC Medical Education. 2005;5(1):1. doi:10.1186/1472-6920-5-1 read 9 October 2026. doi.org/10.1186/1472-6920-5-1
  18. Greenhalgh T, Robert G, Macfarlane F, Bate P, Kyriakidou O. Diffusion of innovations in service organizations: systematic review and recommendations. Milbank Quarterly. 2004;82:581-629. doi:10.1111/j.0887-378X.2004.00325.x read 9 October 2026. doi.org/10.1111/j.0887-378X.2004.00325.x
  19. Grimshaw JM, Eccles MP. Is evidence-based implementation of evidence-based care possible? Medical Journal of Australia. 2004;180(6):S50. doi:10.5694/j.1326-5377.2004.tb05945.x read 9 October 2026. doi.org/10.5694/j.1326-5377.2004.tb05945.x
  20. Buchan H, Sewell JR, Sweet M. Translating evidence into practice. Medical Journal of Australia. 2004;180(6):S43. doi:10.5694/j.1326-5377.2004.tb05942.x read 9 October 2026. doi.org/10.5694/j.1326-5377.2004.tb05942.x
  21. Grol R, Wensing M. What drives change? Barriers to and incentives for achieving evidence-based practice. Medical Journal of Australia. 2004;180(6):S57. doi:10.5694/j.1326-5377.2004.tb05948.x read 9 October 2026. doi.org/10.5694/j.1326-5377.2004.tb05948.x
  22. Grant J, Green L, Mason B. Basic research and health: a reassessment of the scientific basis for the support of biomedical science. Research Evaluation. 2003;12:217-224. doi:10.3152/147154403781776618 read 9 October 2026. doi.org/10.3152/147154403781776618
  23. Mainz J. Defining and classifying clinical indicators for quality improvement. International Journal for Quality in Health Care. 2003;15(6):523-530. doi:10.1093/intqhc/mzg081 read 9 October 2026. doi.org/10.1093/intqhc/mzg081
  24. Grol R, Grimshaw J. From best evidence to best practice: effective implementation of change in patients' care. Lancet. 2003;362:1225-1230. read 9 October 2026. epistemonikos.org
  25. Hulscher MEJL, Laurant MGH, Grol RPTM. Process evaluation on quality improvement interventions. Quality and Safety in Health Care. 2003;12(1):40-46. doi:10.1136/qhc.12.1.40 read 9 October 2026. doi.org/10.1136/qhc.12.1.40
  26. Agency for Healthcare Research and Quality; Department of Veterans Affairs Health Services Research and Development Service. Translating Research into Practice (TRIP) joint program announcement PA-02-066. Agency for Healthcare Research and Quality / NIH Guide for Grants and Contracts. 2002. read 9 October 2026. grants.nih.gov
  27. Ornstein SM. Translating research into practice using electronic medical records: the PPRNet-TRIP project - primary and secondary prevention of coronary heart disease and stroke. Topics in Health Information Management. 2001;22(2):52-58. read 9 October 2026. digital.ahrq.gov
  28. Agency for Healthcare Research and Quality. Translating Research Into Practice (TRIP) II: request for applications RFA-HS-00-008. Agency for Healthcare Research and Quality / NIH Guide for Grants and Contracts. 1999. read 9 October 2026. grants.nih.gov
  29. Sackett DL, Rosenberg WMC, Gray JAM, Haynes RB, Richardson WS. Evidence based medicine: what it is and what it isn't. BMJ. 1996;312(7023):71-72. doi:10.1136/bmj.312.7023.71 read 9 October 2026. doi.org/10.1136/bmj.312.7023.71

Every source above is a peer-reviewed article, a publisher’s record of one, or a standard issued by the body that owns it. Each carries the date it was last read. Where a standard moves, this article is revised rather than left up with a note.

How to cite this article

Pick your referencing style and copy it. Your university or target journal may vary the punctuation — check its guide if it has one.

Pubrica Academy. (2026, October 9). Translating Research into Practice (TRIP) Interventions: Definition and Evidence. Pubrica. https://pubrica.com/academy/concepts-definitions/what-is-triptranslating-research-into-practice-interventions/

This article is written to be learned from. Cite it if you are referring to what it says; if you are using the evidence behind it, cite the sources listed above instead.

TRIP project design and reporting specification

This specification is intended for use at the protocol stage and again before submission. Its questions are those that a methods reviewer in this field typically asks first, and the components section is the one that most proposals are unable to address.

TRANSLATION PROJECT SPECIFICATION

0. TERMINOLOGY
   In this document "TRIP" refers to:
     [ ] the AHRQ funding programme
     [ ] a project funded under that programme
     [ ] a generic translation intervention (state why the label is used)

1. TARGET PRACTICE
   The single recommended action: ___________________________
   Source of the recommendation .: ___________________________
   Certainty of the evidence ....: ___________________________

2. INDICATOR AND BASELINE
   Numerator ....................: ___________________________
   Denominator ..................: ___________________________
   Exclusions ...................: ___________________________
   Data source / extraction .....: ___________________________
   Measured baseline and date ...: ___________________________
   [ ] An independent analyst could reproduce this count

3. PRIMARY OUTCOME  (exactly one)
   Outcome ......................: ___________________________
   Type: [ ] process   [ ] patient
   Powered to detect what difference: ________________________
   [ ] If not powered for a patient outcome, this is stated
   Secondary outcomes (clearly labelled as such): ____________

4. COMPARISON
   [ ] concurrent control sites
   [ ] stepped introduction across sites
   [ ] randomised (unit: ____________)
   [ ] before-and-after ONLY - state the confounders you accept:
       _______________________________________________________

5. COMPONENTS  (one row each; delete any row with no mechanism)
   Component ............: ______________________________
     Mechanism ..........: ______________________________
     Effort: [ ] removes  [ ] redirects  [ ] adds
     Expected persistence after closure: ________________
   Component ............: ______________________________
     Mechanism ..........: ______________________________
     Effort: [ ] removes  [ ] redirects  [ ] adds
   Component ............: ______________________________
     Mechanism ..........: ______________________________
     Effort: [ ] removes  [ ] redirects  [ ] adds
   Components DELIBERATELY EXCLUDED, and why: ______________

6. DELIVERY AND FIDELITY  (these are outcomes, not admin)
   Proportion of intended recipients reached, per component: __
   Fidelity: what is assessed, how, on what sample: __________
   What did people do INSTEAD? method of capture: ____________

7. MAINTENANCE
   [ ] assessed within the project period, method: ___________
   [ ] NOT assessed - this limitation is stated in the paper
   Owner after closure ..........: ___________________________
   Mechanism of persistence .....: ___________________________

8. ECONOMIC CASE, IF MADE
   Translation lag assumed ......: ______ years
   Sensitivity range tested .....: ______ to ______ years
   Return at each end ...........: ______ to ______

STATEMENTS TO DELETE IF PRESENT
  [ ] "multifaceted intervention" with no component mechanisms
  [ ] several co-primary outcomes
  [ ] "we hypothesise significant improvement in patient outcomes"
      in a project not powered for one
  [ ] "research takes 17 years to reach practice"
  [ ] the intervention described as designed rather than as delivered

Pubrica AcademyWritten and maintained by Pubrica’s subject matter experts. Articles are revised when the underlying standards change, and each article states the date on which it was last reviewed.

How Pubrica can help

Pubrica works on translation protocols and reports, checking that the primary outcome is single and labelled, that the comparison can attribute change, that every component carries a mechanism, and that fidelity and delivery appear as outcomes rather than as project administration. Pubrica also removes the two claims that most reliably draw reviewer objections in this field: the 17-year lag asserted as fact, and a patient-outcome hypothesis in a project without the power to test one.

Find something else

Search the Pubrica Academy

Access is free and requires no account. Enter a topic, or open the full library to filter by category, sub-topic or resource type.

Pubrica reviews translation protocols and improvement reports and assesses what a negative result would currently indicate.

A scoping assessment is free and takes two business days. It provides a written assessment of what the work requires and which specialist would undertake it.

Get a free quote

Regulations

Check your project against this rule

  1. 1Your work
  2. 2Your details
  3. 3Send
What do you need?

Material you send is held under signed confidentiality, with access limited to the assigned team and encrypted transfer. It is not used to train anything and is not passed to third-party tools. Ask for the agreement before you send anything you would rather cover first.